Elan eager to expand Tysabri uses

IRISH drug company Elan has begun clinical trials aimed at expanding the treatment possibilities for its headline product Tysabri.

Mostly famous as a treatment for multiple sclerosis, Tysabri is also licensed in the US for use by sufferers of bowel condition, Crohn’s Disease.

Elan — and its co-owner of Tysabri, the American drug giant Biogen Idec — has entered clinical trials for the drug to be used for multiple myeloma, which is the second most common blood cancer in the US.